Abstract
Fifty four postmenopausal women with elevated cholesterol were recruited for a randomised, double-blind controlled trial of soy protein containing isoflavones. (ISP+) or a soy protein with a low isoflavone content (ISP-), taken daily for 12 weeks. There was an overall reduction after 12 weeks in total cholesterol (TC), LDL cholesterol (LDL-C), sex hormone binding globulin (SHBG), and luteinizing hormone (LH). There were no significant differences between treatment groups. In a separate study 27 male subjects with a TC > 5.5 mmol/l were given ISP+ for 12 weeks. In this male study there was a significant increase in HDL cholesterol (HDL-C) and SHBG. Soy protein has a cholesterol lowering effect in both women and men. These studies suggest that this effect is independent of isoflavones. Soy protein also reduces SHBG levels in both sexes.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Alkaline Phosphatase / blood
-
Amino Acids / urine
-
Cholesterol / blood
-
Cholesterol, HDL / blood
-
Cholesterol, LDL / blood
-
Double-Blind Method
-
Female
-
Follicle Stimulating Hormone / blood
-
Humans
-
Hyperlipidemias / drug therapy*
-
Isoflavones / administration & dosage
-
Isoflavones / therapeutic use*
-
Luteinizing Hormone / blood
-
Male
-
Middle Aged
-
Osteocalcin / blood
-
Postmenopause
-
Prospective Studies
-
Sex Characteristics
-
Sex Hormone-Binding Globulin / analysis
-
Soybean Proteins / administration & dosage
-
Soybean Proteins / therapeutic use*
-
Thyrotropin / blood
-
Triglycerides / blood
Substances
-
Amino Acids
-
Cholesterol, HDL
-
Cholesterol, LDL
-
Isoflavones
-
Sex Hormone-Binding Globulin
-
Soybean Proteins
-
Triglycerides
-
Osteocalcin
-
Luteinizing Hormone
-
Follicle Stimulating Hormone
-
Thyrotropin
-
deoxypyridinoline
-
Cholesterol
-
Alkaline Phosphatase